Key Highlights

  • KPTI was down 9.37 percent at USD 0.6000 in pre-market trading on November 2, 2026.
  • A creditor forbearance period was extended to 11:59 p.m. Eastern on November 1, 2026, according to an 8-K dated October 22, 2026.
  • The last close cited was USD 0.6620 on October 30, 2026.
  • Fiscal 2025 Revenue was USD 146.1 million with a net loss of USD 196.0 million.
  • Market Capitalization was roughly USD 15.1 million on about 22.7 million shares.

What moved the stock in pre-market trading

Karyopharm Therapeutics (NASDAQ:KPTI) was down 9.37 percent at USD 0.6000 in pre-market trading on November 2, 2026. Against the USD 0.6620 close of October 30, 2026, that decline is consistent with the quoted move (calculated).

No new company announcement dated November 2, 2026 was identified. The most relevant recent event is the expiry of a creditor forbearance period on November 1, 2026, the final calendar day before this session opened.

The forbearance deadline in detail

In an 8-K dated October 22, 2026, the company said the forbearance period under its agreement with creditors was extended from October 22, 2026 to 11:59 p.m. Eastern on November 1, 2026, unless terminated earlier. The filing listed no conditions for the extension and gave no cash figures.

An earlier extension had pushed the deadline to October 22, 2026. A regulatory filing dated September 11, 2026 warned that cash may last only until a set date in 2026 after Loan and note defaults. A filing dated September 18, 2026 described creditors gaining a senior position that can convert into common shares. No filing describing the outcome after November 1, 2026 was found.

Business background and recent results

Karyopharm is a commercial-stage oncology company that markets XPOVIO, an oral drug for certain blood cancers, and develops related candidates.

For fiscal 2025, the company reported revenue of USD 146.1 million, a net loss of USD 196.0 million and Operating Cash Flow of negative USD 75.4 million. Second-quarter 2026 results were released on August 13, 2026. No third-quarter 2026 results had been located as of November 2, 2026.

Balance sheet and risks

Financing disclosures reference 9.00 percent senior secured convertible notes due 2028 and 2029, and conversion rights could dilute existing holders. The shares closed below USD 1 on October 30, 2026, and the stock was down about 45.7 percent over the prior month, per market data.

As a penny stock, KPTI can swing sharply on thin liquidity, and further dilution or a restructuring would affect common shareholders. On October 19, 2026, a Form 4 showed the chief accounting officer sold 4,788 shares at USD 0.34 on October 16, 2026, reportedly to cover vesting taxes.

What to watch next

Investors will look for a filing that states whether the forbearance was extended again, ended or replaced by a restructuring agreement. Third-quarter results, any update on the cash runway and any listing notice tied to the sub-USD 1 price are the other markers.

Pre-market moves on low Volume can reverse once the regular session opens, so confirmation from company filings matters more than the early print.